Navigation Links
Linnartz New Head of Investor Relations of Gerresheimer
Date:11/7/2007

DUSSELDORF, Germany, November 7 /PRNewswire/ -- Anke Linnartz (38) is to assume responsibility for managing the Investor Relations Department of Gerresheimer AG from January 1, 2008. In this position she will report to Chief Financial Officer Hans-Jurgen Wiecha. Gerresheimer, a leading international supplier of high-quality packaging solutions based on glass and plastic for the pharmaceutical and life science industry, has been listed on the Frankfurt stock exchange since June 2007 and was included in the S-DAX shortly after its IPO. Linnartz currently runs the IR department of the S-DAX company Demag Cranes AG.

Gerresheimer is a pharmaceutical & life science supply and services company with market leading positions of specialty products made of glass and plastic. Gerresheimer owns 37 production sites in Europe, North America and Asia and employs approximately 10,000 employees worldwide.

Contact

Burkhard Lingenberg

Director Corporate PR & Marketing

Telephone: +49-211-6181-250

Telefax: +49-211-6181-241

e-mail: b.lingenberg@gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Skinvisible to Present at Merriman Curhan Ford & Co.s Investor Summit 2007
3. DURECT to Present at Merriman Curhan Fords Annual Investor Summit
4. Exponent to Present at the Upcoming Sidoti & Company Investor Forum and William Blair Small-Cap Growth Stock Conference
5. Stryker to Present at Investor Conference
6. AMERIGROUP Corporation to Host Investor Day
7. Milestone Scientific to Present at the Edgewater Research Investor Conference
8. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
9. Par Pharmaceutical Provides Summary of Analyst/Investor Day
10. Sunnylife Global Retains The Blaine Group For Investor Relations, Financial Public Relations
11. SGX Pharmaceuticals to Present at the BIO InvestorForum 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... ... The John P. McGovern Museum of Health and Medical Science is now partnered ... and share results with their physicians. Members and guests can sign up for its ... founder, Dr. David Eagleman, formerly at Baylor College of Medicine and now at Stanford ...
(Date:4/24/2017)... Waycross, Ga. (PRWEB) , ... April 24, 2017 ... ... and trusted advisor within the telehealth industry, announces the company’s VideoMedicine mobile platform ... primary care providers. Available 24 hours a day, Quick Care provides patients with ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... to recognize elevated anxiety levels in people with addiction who are served by ... Patch, a biosensing wearable device that monitors heart and breath rates to identify ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa ... Walter Blvd, for an educational and exciting 2-day program. , An attendee at ... this before they approach patients” about the course entitled Ain't Misbehavin': Decreasing and Managing ...
(Date:4/24/2017)... ... ... “Reflections of God’s Work”: an enlightening collection of life lessons leading each ... published author, Jerri Broglin, a survivor of great loss who gained insight on how ... for those searching for answers, as we are finding the answers that are so ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray product ... a healthy CAGR during the forecast period Mobile ... the global digital mobile X-Ray devices market, which is estimated ... 2017, expanding at a CAGR of 7% over the forecast ... opportunity of more than US$ 100 Mn in 2017 over ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology: